Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Treatment patterns and clinical outcomes among patients with biliary tract cancers in a large commercially insured US population.
Authors
Adriana Valderrama
Merck & Co., Inc., Kenilworth, NJ
Adriana Valderrama , Mukul Singhal , Liya Wang , Bal Nepal , Shital Kamble , Michael Grabner , Usha Malhotra , Milind M. Javle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
DOI
10.1200/JCO.2022.40.4_suppl.398
Abstract #
398
Poster Bd #
M7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma.
First Author: Guru P. Sonpavde
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Epidemiological biliary tract cancer characterization: A patient cohort from the Spanish RETUD registry.
First Author: Teresa Macarulla
Poster
2021 ASCO Annual Meeting
Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma.
First Author: Daniel M. Geynisman
Poster
2019 Gastrointestinal Cancers Symposium
Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.
First Author: Aaron C. Tan